Therapeutics News

Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.

Ycanth has received a permanent J-code from the Centers for Medicare & Medicaid Services, Verrica Pharmaceuticals announced in a press release.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

A potassium titanyl-phosphate laser has shown to have similar efficacy and less pain when compared with pulsed dye lasers in treating port wine birthmarks, according to a study.

Following the bankruptcy of Timber Pharmaceuticals, LEO Pharma has finalized the acquisition of TMB-001 and other assets from Timber, according to a press release.

Video education about topical corticosteroids alleviated caregivers’ concerns and improved outcomes for pediatric patients with eczematous dermatitis, according to a study published in Pediatric Dermatology.

Compared with unvaccinated individuals, the recombinant zoster vaccine reduces the 3-year risk for mortality and myocardial infarction among individuals aged 50 to 65 years, according to a study.

Verrica reported a net loss of $24.8 million, or $0.54 per share in the third quarter of 2023, according to a press release. The company had a net income of $83,000 in the same period last year.

Acitretin in combination with topical triamcinolone acetonide 0.1% may be a better treatment option than triamcinolone acetonide alone for patients with oral lichen planus, according to a study.

Patients treated with phototherapy without psoralens do not experience higher incidence rates of skin cancer compared with the general population, according to a study.